| Similar Articles |
|---|
 |
The Motley Fool
January 18, 2008
Brian Orelli |
The Battle of the Thrombins ZymoGenetics announces that its recombinant thrombin product, Recothrom, was given a thumbs-up by the FDA.   |
The Motley Fool
January 14, 2009
Brian Orelli |
ZymoGenetics, the Pharmaceutical Zombie ZymoGenetics deal with Bristol-Myers may bring the drug developer stumbling back from the dead. |
The Motley Fool
November 5, 2008
Brian Orelli |
ZymoGenetics Leads With Its Chin It says a lot about ZymoGenetics' quarter that management decided to open its conference call talking about its hepatitis C drug still in trials, rather than the sales results of its blood-clotting agent, Recothrom. |
The Motley Fool
September 6, 2006
Brian Lawler |
Catalyst for ZymoGenetics? Trial results for a drug that controls bleeding include a favorable comparison with a similar product. Investors, take note. |
The Motley Fool
August 28, 2007
Brian Orelli |
FDA Makes Cows Happy The FDA approves Omrix's human-derived thrombin, which replaces a version made from cattle. |
The Motley Fool
May 13, 2008
Brian Orelli |
Omrix's Wild Ride High-growth stocks like Omrix Pharmaceutical can be hard to value. Not only are growing revenues hard to predict, but expenses can fluctuate wildly as the company grows. |
The Motley Fool
August 23, 2007
Brian Orelli |
Can't Stop the Bleeding From a Paper Cut ZymoGenetics' rThrombin product is delayed. With a 9% drop in stock price, it looks like investors are overreacting. |
The Motley Fool
September 7, 2010
Luke Timmerman |
ZymoGenetics, Seattle Biotech Pioneer, Acquired by Bristol-Myers for $885 Million The two companies have gotten to know each other quite well since January 2009, when Bristol agreed to pay as much as $1.1 billion for the right to co-develop and co-market a drug for hepatitis C. |
The Motley Fool
September 30, 2010
Brian Orelli |
Bristol-Myers' Delayed Steal ZymoGenetics price tag looks more reasonable. |
The Motley Fool
May 15, 2007
Brian Lawler |
King Fights for Its Empire King Pharmaceuticals announces another good quarter of financial results. Investors should expect more product acquisitions in the coming years. |
The Motley Fool
September 12, 2008
Brian Lawler |
King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders. |
The Motley Fool
February 24, 2010
Brian Orelli |
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Bristol-Myers Almost Ready to Seal the Deal With ZymoGenetics ZymoGenetics, one of the driving forces of Seattle biotech the past 30 years, is about to become a thing of the past. |
The Motley Fool
May 20, 2010
Brian Orelli |
FDA Transparency! A Big Win for Investors The Food and Drug Administration has possibly just made things easier for investors. Let's just hope drug companies don't shoot it down. |
The Motley Fool
May 16, 2007
Mike Havrilla |
ZymoGenetics Is Poised to Stop Bleeding With shares of ZymoGenetics currently trading near three-year lows, now may be a good time to pick some up. |
Managed Care
December 2007
Thomas Morrow |
Human-Derived Clotting Agent Avoids Immunogenicity Evithrom may minimize some of the antibody production associated with bovine proteins, but the possibility of human viral infection exists. |
The Motley Fool
February 27, 2004
Zeke Ashton |
King Makes a Comeback The love/hate cycle might be ready to shift again for this pharmaceutical. King Pharmaceuticals was once a beloved growth stock. Then it became an unloved drug stock suffering from intensifying competition, a poor acquisition or two, and an ongoing SEC investigation. The stock has started to come back. |
The Motley Fool
January 28, 2009
Brian Orelli |
A Mini-Pfizer in the Making Bristol-Myers Squibb looks like its setting itself up to be the next Pfizer. |
Pharmaceutical Executive
June 1, 2006
Sara Calabro |
King Without the Crown While most of pharma tries to convince the world that R&D is the number-one priority, one specialty company, King Pharmaceuticals, boasts that it has no lab. |
The Motley Fool
September 6, 2007
Brian Orelli |
Foolish Fantasy Football: 3 Drug Companies The pro football season kicks off tonight. Our fantasy team might just help you tear up the investing gridiron! Here's the starting lineup. Barr Pharmaceuticals... GlaxoSmithKline... etc. |
The Motley Fool
November 6, 2006
Brian Lawler |
One Step at a Time ZymoGenetics' management is still facing challenges, but so far it has proved itself worthy to investors. |
